Attruby sales exceed $500 million in first year by Nov 23, 2025? | Binary | | | 1 month ago | |
Will BridgeBio's stock price ($BBIO) remain above $40 by December 31, 2024? | Binary | | | 3 months ago | |
Will the FDA grant full approval for BridgeBio's infigratinib by September 30, 2025? | Binary | | | 3 months ago | |
What will BridgeBio's stock price ($BBIO) be by December 31, 2024? | Categorical | | | 3 months ago | |
Will BridgeBio's infigratinib complete Phase 3 clinical trials successfully by June 30, 2025? | Binary | | | 3 months ago | |
Pfizer launches new ATTR-CM treatment in US by Dec 31, 2025? | Binary | | | 1 month ago | |
Average annual cost of ATTR-CM treatments in US by Dec 31, 2025? | Categorical | | | 1 month ago | |
Highest revenue growth rate for ATTR-CM companies in 2025? | Categorical | | | 1 month ago | |
FDA issues safety warning or recall for Attruby by Nov 23, 2025? | Binary | | | 1 month ago | |
Largest US market share for ATTR-CM treatments by Dec 31, 2025? | Categorical | | | 1 month ago | |
Where will BridgeBio's infigratinib be approved by September 30, 2025? | Categorical | | | 3 months ago | |
What will be the status of BridgeBio by September 30, 2025? | Categorical | | | 3 months ago | |
